Last updated: 2026-09-16 12:18:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
uniQure N.V. (QURE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $43,43, with a market capitalisation of $3,12B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8,73 to $71,50. This page covers its latest market performance, valuation, price trends and company information.
$3,12B | |
$43,25 | |
$82,49 | |
$3,73 | |
$43,10 | |
64,76K | |
1,84M | |
-- | |
$71,50 | |
$8,73 | |
-- | |
-- |
uniQure N.V. (QURE) is trading at $43,43 in pre-market trading as of 2026-09-16 12:14:00, up 0,76% ($0,33) from the previous close of $43,10
Pre-market trading shows how investors are pricing QURE before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, uniQure N.V. (QURE) moved from $44,50 to $43,43, representing a decline of 2,41% ($1,07).
The stock traded between $41,74 and $46,98 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1,12 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55,3%
QURE is currently trading at $43,43, placing it 55,3% of the way from its 52-week low of $8,73 to its 52-week high of $71,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 221 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of uniQure N.V. (QURE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.